Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2770-2779

  Villalona Calero, Miguel A ^a   Baker, Sharyn D ^a   Hammond, Lisa ^a   Aylesworth, Cheryl ^a   Eckhardt, S Gail ^a   Kraynak, M ^a   Fram, Robert ^a   Fischkoff, Steven ^a   Velagapudi, Raja ^a   Toppmeyer, Deborah ^a   Razvillas, Betty ^a   Jakimowicz, Krystyna ^a   Von Hoff, Daniel D ^a   Rowinsky, Eric ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEMADOTIN; DOLASTATIN; DOLASTATIN DERIVATIVE; N,N DIMETHYLVALYLVALYL N METHYLVALYLPROLYLPROLINEBENZYLAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SOLUBILITY; EDEMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031903252     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2770     Document Type: Article

References (19)

1. Pettit G, Kamano Y, Dufresne C, et al: Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 54:6005-6006, 1989
2. Pettit G, Kamano Y, Fujii Y, et al: Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod 44:482-485, 1981
3. Pettit G, Kamano Y, Herald C, et al: The isolation and structure of a remarkable marine antineoplastic constituent: Dolastatin 10. J Am Chem Soc 109:6883-6885, 1987
4. Pettit GR: The dolastatins. Prog Chem Organic Nat Prod 70:1-79, 1997
5. Quentmeir H, Brauner S, Pettitt G, et al: Cytostatic effects of dolastatin 10 and dolastatin 15 on human leukemia cell lines. Leuk Lymph 6:245-250, 1992
6. Hu Z, Gignac S, Quentmeier H, et al: Effects of dolastatins on human B-lymphocytic leukemia cell lines. Leuk Res 4:333-339, 1993
7. Beckwith M, Urba W, Longo D: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85:483-488, 1993
8. Bai R, Pettit G, Hamel E: Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharm 39:1941-1949, 1990
9. Bai R, Friedman S, Pettit G, et al: Dolastatin 15, a potent antimitotic depsipeptide derived from Dollabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharm 43:2637-2645, 1992
10. De Arruda M, Cocchiaro C, Nelson C, et al: LU103793 (NSC D-669356): A synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 55:3085-3092, 1995
11. Smith P, Nelson C, Janssen B, et al: Pre-clinical anti-tumor activity of a novel water-soluble dolastatin 15 analog (LU103793). Proc Am Assoc Cancer Res 36:393, 1995 (abstr 2345)
12. Villalona-Calero M, Degen D, Barlozzari T, et al: LU103793: Evaluation by human tumor clonogenic assay of a novel dolastatin. Proc Am Assoc Cancer Res 36:394, 1995 (abstr 2349)
13. Smith P, Nelson C, Spigelman M, et al: In vivo anti-tumor activity of LU103793: Evidence for schedule dependency in MX-1, KB3- 1 and P388 tumor models. Proc Am Assoc Cancer Res 36:394, 1995 (abstr 2348)
14. Mross K, Herbst K, Berdel W, et al: Phase I clinical and pharmacokinetic study of LU103793 (cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. Onkologie 19:490-495, 1996
15. Wolff I, Bruntsch U, Cavalli F, et al: Phase I clinical and pharmacokinetic study of the dolastatin analogue LU103793 on a weekly × 4 schedule. Ann Oncol 7:124, 1996 (abstr 595, suppl 5)
16. Cockroft D, Gault M: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
17. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
18. Lalonde RL: Pharmacodynamics, in Evans WE, Schentag JJ, Jusko WJ (eds): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics, Vancouver, WA, 1992, pp 4-1 to 4-33
19. Tokaz L, Von Hoff D: The cardiotoxicity of anticancer agents, in Perry M, Yarbro J (eds): Toxicity of Chemotherapy. New York, NY, Grune & Stratton, 1984, pp 199-226